Denise Mann is a freelance health writer based in New York. She specializes in medicine and healthcare, exploring topics such as dermatology, wellness programs, and the beauty industry, with a focus on aging and longevity. Denise's work has been featured in numerous outlets, including HealthDay News, Reader's Digest, and BuzzFeed News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Denise Mann's coverage predominantly focuses on healthcare, pharmaceuticals, and scientific topics related to dermatology and skin conditions. The majority of her articles cite data or are based on press releases. She appears to be interested in reporting on the latest medical research, FDA approvals, and developments within the field of skincare.
When reaching out to Denise Mann with pitches or expert commentary, consider offering access to new research findings, exclusive insights into clinical trials for dermatological treatments or FDA approval processes. Providing access to experts who can offer unique perspectives on emerging trends in dermatology and skin care could also be well received by Denise.
Given that there is no specified geographic focus for Denise Mann's work, she may cover global developments within dermatology and skin care fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Denise Mann
Oral povorcitinib (Incyte) showed significant improvements in Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) vs. placebo and a favorable safety profile in adults with moderate-to-severe hidradenitis suppurativa (HS) through Week 54, new research shows. The study, which is published in Nature Medicine, provides the complete peer-reviewed dataset for the previously reported results from the Phase 3 […]
By: Denise Mann
Peptides are all the rage these days, and many are hyped online by wellness influencers for everything from weight loss and longevity to insomnia and tanning. They are sold freely on the ‘grey market,’ and now, an advisory committee for the US Food and Drug Administration (FDA) has voted to add six peptides to a […]
Health Canada has issued a Notice of Compliance (NOC) for remibrutinib (Rhapsido, Novartis) for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. A NOC is a formal green light from Health Canada allowing a manufacturer to market a new drug after a successful safety and effectiveness […]
By: Denise Mann
In this column, The Dermatology Digest (TDD) highlights some of the newest launches in the skincare space. SkinCeuticals Next-generation C E Ferulic Serum SkinCeuticals is rolling out the next generation of C E Ferulic. While honoring the original formula—featuring 15% Pure Vitamin C, 1% Vitamin E, and 0.5% Ferulic Acid—the next-generation C E Ferulic includes […]
And the winners of the 2026 International League of Dermatological Societies (ILDS) Certificates of Appreciation are… The 2026 ILDS Certificates of Appreciation—Humanitarian Dermatology This award recognizes individuals whose work has improved dermatological care and skin health in underserved communities through the delivery of humanitarian or not-for-profit initiatives, including: Reynaldo Arosemena Sarkissian, MD, IFAAD, Panama Professor […]
By: Denise Mann
This recurring column features the latest executive appointments, promotions, and leadership changes across the dermatology industry. New CEO at STRATA Skin Sciences Erica Jordan is the new Chief Executive Officer of STRATA Skin Sciences, Inc. Prior to joining STRATA, Ms. Jordan served as Chief Commercial Officer for Revance Therapeutics. Prior, she served as Metrex president […]
By: Denise Mann
The first national mass drug administration (MDA) control program for scabies has drastically reduced cases of the skin disease in Solomon Islands and Fiji, a new study shows. The research, led by the World Scabies Program (WSP) at Murdoch Children’s Research Institute (MCRI) in Victoria, Australia, and published in Nature Health, found the MDA program—which […]
By: Denise Mann
Ritlecitinib (Litfulo, Pfizer) is showing promise in nonsegmental vitiligo, according to positive topline results from two Phase 3 trials, The TRANQUILLO study included patients aged 12 years and up, while TRANQUILLO 2 enrolled adults only. Across the studies, both the 50mg and 100mg doses of ritlecitinib delivered significant, clinically meaningful improvements over placebo on co-primary […]
By: Denise Mann
Antihistamines don’t ease eczema symptoms, and some may increase the risk of cognitive impairments, finds new research in BMJ. To arrive at their findings, researchers conducted a systematic review of 47 randomized trials consisting of 6,230 children and adults (average age 20 years; 52% female) with mainly moderate-to-severe eczema. They used the McMaster-developed grading of […]
The US Food and Drug Administration’s (FDA) FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted that the benefit-risk profile of vusolimogene oderparepvec (RP1, Replimune) in combination with nivolumab (Opdivo, Bristol Myers Squibb) is favorable for adults with advanced melanoma who have progressed on prior anti-programmed cell death protein 1(anti–PD-1)–containing therapy, according to media reports. […]
